Article Contribution by Optometrist Alysha
Anti-VEGF injections such as with Eylea have successfully allowed many patients with macular degeneration to maintain their vision and quality of life for over a decade now. Anti-VEGF injections however are only effective for the wet type of macular degeneration where there is leakage and not for the dry type of macular degeneration characterized by thinning and degeneration of the retina (atrophy).
For the first time, patients with geographic atrophy (GA) secondary to late stage macular degeneration will have access to effective treatment. Syfovre® (pegcetacoplan) has been approved for use in Australia by the Therapeutic Goods Administration (TGA) on 27 January 2025. It is suitable for patients with good central vision with an intact fovea but at risk of losing their central vision from progression of the GA lesion. Treatment is performed every other month. The aim of therapy is to stabilize and reduce progression of vision loss, enabling patients to maintain their independence.
Syfovre has been approved in the United States since February 2023. Clinical trials (OAKS and DERBY) have demonstrated a decrease in the progression of GA with Syfovre. We are excited about this significant milestone in the AMD armamentarium and look forward to offering this new treatment at City Eye Centre when it becomes available. If you would like further information on how this new intravitreal injection may help you, please contact us on 07 3831 6888 or email us at appointments@cityeye.com.au.